Announcing Mitra Bio as Tier 3 Sponsor of ARDD 2025

Empowering the future of aging research: Mitra Bio to sponsor ARDD 2025, the world's largest conference on aging research in the biopharmaceutical industry

2025-08-01

(Press-News.org) The University of Copenhagen is excited to announce Mitra Bio as Tier 3 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.

“ARDD sits at the intersection of frontier longevity science and real-world impact—exactly where Mitra Bio wants to be,” said Shakiba Kaveh, PhD, co-founder & CEO of Mitra Bio. “By sponsoring this year’s meeting, we hope to support the longevity science community and share our insights and learnings from operating in the skin aging space in the last five years, bringing non-invasive skin epigenetic testing to skincare, medical device, and pharmaceutical companies.”

ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.

“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.

“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.

“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.

Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.

About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.

For further information, images or interviews, please contact:

ardd@pharma.ai

About Mitra Bio

Mitra Bio is a London-based biotechnology company pioneering non-invasive skin epigenetic testing. Its patent-pending, tape-strip sampling and next-generation sequencing workflow provides deep epigenetic insights to skincare, medical device, and pharmaceutical partners, replacing traditional biopsies with fast, painless testing. Mitra Bio’s mission is to enable skin longevity and improve patient care through the power of epigenetics.

For more information, visit mitrabio.tech, or follow us on LinkedIn.

Mitra Bio media contact

Jay Yeung, jay@mitrabio.tech

END

ELSE PRESS RELEASES FROM THIS DATE:

Study identifies global upswing in photosynthesis driven by land, offset by oceans

2025-08-01

Terrestrial plants drove an increase in global photosynthesis between 2003 and 2021, a trend partially offset by a weak decline in photosynthesis — the process of using sunlight to make food — among marine algae, according to a new study published in Nature Climate Change on Aug. 1. The findings could inform planetary health assessments, enhance ecosystem management, and guide climate change projections and mitigation strategies. Photosynthetic organisms — also known as primary producers — form the base of the food chain, making most life on Earth possible. Using ...

Study reports final clinical trial data for advanced kidney cancer treatment

2025-08-01

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine. The study reports final clinical data and biomarker analyses from the Phase 3 KEYNOTE-426 trial, which compared the drug combination pembrolizumab plus axitinib versus the single drug sunitinib for patients with previously untreated advanced clear cell renal cell carcinoma, the most common type of kidney cancer. “KEYNOTE-426 was the first trial to combine a PD-1 ...

Antibiotic resistant bacteria found in malnourished children under five years old

2025-08-01

A new study led by researchers at the Ineos Oxford Institute for antimicrobial research (IOI) has found that antimicrobial resistant bacteria is spreading rapidly among children being treated for severe malnutrition in a hospital facility in Niger. The findings have been published today (1 August) in Nature Communications Globally 45 million children under the age of five are estimated to be severely malnourished. These children are also at a higher risk of developing life-threatening infections such as tuberculosis or sepsis due to their weakened immune systems. Working with Médecins Sans Frontières (Doctors Without Borders), researchers analysed over 3,000 ...

Study: Most US homes can save money and affordably weather blackouts with solar plus storage

2025-08-01

Most U.S. households could reduce their electricity costs and endure power outages by installing rooftop solar panels and battery packs, according to a new Stanford University study, though people may need to buy the equipment by Dec. 31. About 60% of families could reduce their electricity costs by 15% on average by installing a solar-battery system. That’s after accounting for annualized capital and operating costs of the equipment. Some 63% of U.S households could also weather local or regional blackouts with such systems, able to meet about half their electricity needs on average. These households would either save money on electricity or ...

The human touch of doctors will still be needed in the AI healthcare revolution, technology expert suggests

2025-08-01

AI-based medicine will revolutionise care including for Alzheimer’s and diabetes, predicts a technology expert, but it must be accessible to all patients. Healing with Artificial Intelligence, written by technology expert Daniele Caligiore, uses the latest science research to highlight key innovations assisted by AI such as diagnostic imaging and surgical robots. From exoskeletons that help spinal injury patients walk to algorithms that can predict the onset of dementia years in advance, Caligiore explores what he describes as a ‘revolution’ ...

Helping me, inhibiting you: Analysis of interactions between intestinal microbiota

2025-08-01

Intestinal bacteria are important for human health as they help digest food and regulate immune function. Thus, in recent years, it has become clear that gut microbiota dysbiosis, an imbalance in types and composition of intestinal bacteria, is associated with digestive disorders and other diseases. However, the mechanism by which bacteria interact in the intestine to maintain the microbiota balance remains unclear. A research group led by Associate Professor Koji Hosomi at Osaka Metropolitan University’s Graduate School of Veterinary Science studied two bacteria: Fusobacterium varium (F. varium), an oral and intestinal bacterium linked to inflammation and colon ...

Hearing loss lowers prospects of employment and higher income for young Americans

2025-08-01

Hearing loss is the most common form of sensory disability. Approximately 1.6 billion people around the world currently live with from some degree of hearing loss, and the WHO has forecast that this number will rise to 2.5 billion by 2050. People with hearing loss tend to experience more stress and anxiety at school or work, and as a result take more days off sick. The annual global cost of unaddressed hearing loss may run to $1 trillion. Now, a long-term observational study has found that young adults with hearing difficulties in the US have less educational ...

Dramatically lower temperature, same high performance!

2025-08-01

Dr. Jung-Dae Kwon's research team at the Energy & Environmental Materials Research Division of the Korea Institute of Materials Science (KIMS, President Chul-Jin Choi) has successfully developed an amorphous silicon optoelectronic device with minimal defects, even using a low-temperature process at 90°C. Notably, the team overcame the limitations of high-temperature processing by precisely controlling the hydrogen dilution ratio—the ratio of hydrogen to silane (SiH₄) gas—enabling the fabrication of high-performance ...

Trigger warnings fall flat, but safe spaces build trust in the classroom

2025-08-01

Trigger warnings may not help students feel more supported, but safe space messages do. A new study found that being told they were in a ‘safe space’ made students feel more comfortable, trusting, and positive toward the person delivering them. Researchers from Flinders University and collaborators in the United States studied the responses of 738 U.S based university students. Each student watched a short trauma-related lecture introduced by an instructor with either a trigger warning, a safe space message, both, or neither. Students ...

Searching for a lethal needle in a haystack: synthetic opioid 1000 times more potent than morphine

2025-08-01

A synthetic opioid 1000 times more potent than morphine is infiltrating the street drug trade in Adelaide, Australia, sparking fears of a wave of overdoses that could be lethal. In the first study of its kind in South Australia, University of South Australia researchers have detected traces of nitazene in samples of discarded injecting equipment, plastic bags, vials and filters from public disposal bins at local needle and syringe program sites. Their findings are published today in the Drug & Alcohol Review. Using highly sensitive ...